Comments
Commented by Fabian Lorenz on September 18th, 2025 | 07:25 CEST
Adidas to take over Puma? Evotec with insider buying! 50% upside potential with AI stock NetraMark!
Adidas and Puma caught in merger fever? A US investor brings the spectacular idea into play. Is it a means of exerting pressure on Puma's management or a real possibility? What do analysts say? Meanwhile, Evotec is sending a signal of confidence with fresh insider purchases. However, the stock is still digesting the recent revenue forecast downgrade. Could there be fresh momentum next week? In contrast, NetraMark shares offer a 50% return. For this to happen, however, the AI-driven drug development specialist must reach the analysts' price target. Operationally, there is much to be said for this, and in comparative tests, the Company has outperformed ChatGPT and DeepSeek.
Read
Commented by André Will-Laudien on September 18th, 2025 | 07:20 CEST
Margins war and soaring commodity prices! Caution advised on BYD, Mercedes, RENK, and European Lithium
So far, September has turned out to be a month of bliss. It appears that the stock market already underwent its full correction back in April. Investors are still buying high-tech and AI stocks, seemingly unconcerned by valuations of historic proportions. In the wake of this super bull market, automakers BYD and Mercedes have recently suffered significant price corrections. At the same time, the wave of euphoria surrounding defense stock RENK now appears somewhat exaggerated. The rally around critical metals has also driven European Lithium and its US subsidiary Critical Metals significantly higher. With commodity prices recently exploding, however, the rally here is likely only just beginning. We take a closer look at the numbers.
Read
Commented by Armin Schulz on September 18th, 2025 | 07:15 CEST
Novo Nordisk, PanGenomic Health and Pfizer - Who are the winners of the digital health revolution?
The disruptive force of the digital health revolution is fundamentally changing the healthcare industry. Artificial intelligence, data-driven therapies, and digital diagnostics are opening up billion-dollar markets and catapulting agile players to the forefront. These pioneers are setting new standards in patient-centered care and generating exponential growth in the process. This ecosystem opens up unique opportunities for strategic investors. Today, we take a look at Novo Nordisk's restructuring, PanGenomic Health's AI-driven innovations, and the political uncertainties at Pfizer.
Read
Commented by Fabian Lorenz on September 18th, 2025 | 07:10 CEST
MAJOR DEVELOPMENTS for megatrend stocks: Rheinmetall, BioNTech, First Hydrogen
Rheinmetall is going full throttle: on land, at sea, in the air, and even in space. Its latest bombshell is the announced takeover of Lürssen's naval division. Will this provide the tailwind the stock needs to break through the EUR 2,000 mark on a sustained basis? Analysts view the transaction positively, though some cautionary voices remain. Meanwhile, a major development in Canada is boosting sentiment around First Hydrogen. North Americans aim to be at the forefront of the small modular reactors (SMRs) movement. The potential is enormous. BioNTech also holds significant promise in the fight against cancer. However, challenges have emerged - ironically in the world's largest pharma market. The US government plans to cut or even stop funding for new mRNA vaccine development. BioNTech shares reacted accordingly and may break through their sideways trend downwards.
Read
Commented by Nico Popp on September 18th, 2025 | 07:05 CEST
Understanding metabolism, generating returns: Vidac Pharma, Roche, AstraZeneca
In the search for new treatments against diseases, researchers agree on one thing: the holy grail is unlikely to be found. Instead, it is incremental improvements and combination therapies that promise progress in complex diseases such as cancer. Cell metabolism is considered a promising approach, for example, in cancer, when the metabolism of a cancer cell is disrupted, the cell dies. In this article, we present current approaches and also discuss a biotechnology company that is wholly dedicated to cellular metabolism.
Read
Commented by Carsten Mainitz on September 18th, 2025 | 07:00 CEST
Almonty Industries, thyssenkrupp, Nordex – Perfect news!
Rare earths and critical raw materials play a vital role across many sectors of the economy. They are essential for electric motors, permanent magnets, and battery technologies and are of great importance in the defense industry. China controls the majority of global reserves and is restricting exports. Western countries have long been making great efforts to secure deposits outside China, with particular pressure coming from the US. A recently published report by Bloomberg has raised eyebrows.
Read
Commented by Nico Popp on September 17th, 2025 | 07:30 CEST
Bundesbank causes a sensation in the silver market: Silver North Resources, Fresnillo, Wheaton Precious Metals
Silver prices continue to rise. As a result, the face value of German silver coins is now also increasing—otherwise, the gap between the face value and the actual material value of the investment coins would become too significant. This upward trend is driven both by growing global uncertainty and increasing industrial demand. In addition to the photovoltaic and chip industries, silver is also increasingly being used in defense applications. We present three companies from the silver sector and highlight investment opportunities.
Read
Commented by Fabian Lorenz on September 17th, 2025 | 07:25 CEST
CAUTION with Nordex and thyssenkrupp! ENTRY OPPORTUNITY with Power Metallic Mines!
Commodity stocks remain promising. They are the backbone of technological progress—especially in an AI-driven world. And precious metals are considered a safe haven. Power Metallic Mines benefits from both trends with its world-class multi-metal project. After months of consolidation, new drilling results could boost the share price, as was the case last year. Caution is advised with Nordex, however. Although this year's surprise stock is impressive with its strong operating business and high order backlog, headwinds from political risks are increasing. Trump in the US and Merz in Germany are weighing on sentiment in key markets. But analysts still recommend buying? At thyssenkrupp, the expected IPO of the naval division TKMS is drawing closer. Full order books support the story, but with Rheinmetall entering the shipbuilding business, competitive pressure is growing significantly.
Read
Commented by Carsten Mainitz on September 17th, 2025 | 07:20 CEST
Globex Mining, Deutz, Novo Nordisk – Prices are rising!
On the stock market, there is often a difference between price and value. Companies with strong assets and holdings, or those with business models that benefit from long-term trends, tend to deliver attractive returns for investors in the long run. All the better if such companies can be acquired at a favorable price - one that lies below the fair value of their shares.
Read
Commented by André Will-Laudien on September 17th, 2025 | 07:15 CEST
Gold explodes to USD 3,700 – What is next? Time to bet on Barrick Mining, Newmont, Dryden Gold and BASF
The gold price is currently being driven primarily by expectations of falling US interest rates, a weaker US dollar, high geopolitical uncertainty, and strong purchases by central banks. The latter added around 1,045 tons of gold to their reserves in 2024, one of the highest levels in recent years. Major US investment banks have consistently raised their price targets: Goldman Sachs expects around USD 3,700 per ounce by the end of 2025, JPMorgan sees an average of about USD 3,675 in Q4, and UBS even forecasts up to USD 3,800. In very optimistic scenarios, prices of over USD 4,000 are already being discussed in industry. How are gold giants Barrick and Newmont performing in this environment? In the short term, they have been significantly outperformed by Dryden Gold, which has recently doubled in value. Investors should now drastically increase their exposure to precious metals, as they have been overinvested in AI, high tech, and defense for months. Here are a few ideas.
Read